street ep
focal pt
 rais ep midpoint
project rais ep rang
midpoint vs our/street even face
ex-u biosimilar humira competit oct sale
in-lin with/beat estim street humira/hcv
out-performance ep our/street
lower sg humira sale yoy mostli in-
line/abov our/street abbv impli
project global expect call focu humira eu
loe oct hem/onc life cycl manag immunolog pipelin orlissa
elagolix launch state see note titl orlissa approv
clean label think ideal posit launch endometriosi
rel clean label partner neurocrin rate
plan ship orilissa aug repres discount
rais lupron depot price sinc expect
opportunist front acquisit rang like
opinion reiter ep support
dcf risk clinical/regulatori commerci execut pipelin humira/
imbruvica ip risk headlin risk fda biosimilar action lead
volatil upcom catalyst includ potenti settlement addit
humira biosimilar manufactur shine/selen data orilissa
immin launch endometriosi uterin fibroid data asrm oct
denver sdna file expect
ep rang impli yoy growth face biosimilar
rais non-gaap ep rang
revis midpoint yoy vs our/street
updat outlook item press
releas remind april expect revenu approach
vs our/street gross margin vs our/
street invest year especi
immunolog hematology/oncolog segment project spend
sale vs our/street sg project
spend approach sale vs our/street
expect tax rate line our/street
exhibit summari financi rang vs our/street estim typic
provid addit color full-year next quarter outlook earn call includ expect
ep rang operational/report revenu growth sale growth key product humira/
sale in-lin strh street humira exh
revenu yoy report ex-fx top abbv expect
oper fx in-lin with/abov our/street driven
global humira hcv viekira mavyret sale beat global humira sale
 abbv impli project humira us sale came
yoy our/street estim in-lin abbv project approach
yoy growth humira ex-u sale yoy vs our/
street estim abbv project humira execut remain strong abbv
immunolog salesforc continu produc robust volume-driven growth despit humira
market decad global hcv mavyret viekira sale came
yoy/qoq our/street est us hcv sale
yoy/qoq our/street estim ex-u hcv sale
yoy/qoq mostli in-lin our/street estim imbruvica global sale
came yoy our/street imbruvica
us sale came vs our/street mostli in-lin abbv project
approach lupron sale yoy our/street
duodopa creon androgel slight miss vs estim
other sevofluran synthroid kaletra exhibit
summari sale vs our/street estim
sales/ep beat vs street
ep yoy our/street estim
revenu in-lin with/beat our/steet compar
estim lower spend interest income/expens partial
off-set higher sg higher share count yield ep gross margin
above/below our/street estim oper expens
 sg came vs our/street estim result
oper incom vs our/street estim tax rate in-lin with/below
our/street yield ep our/street exhibit
summari result vs our/street estim
multipl pipelin catalyst place upward pressur multipl
bounti catalyst reduc investor concern around humira durabl
concentr risk result multipl expans drive out-perform ink deal
rate juli juli launch expect settl
humira biosimilar manufactur near-term notabl boehring ingelheim privat
put defens strategi place protect humira franchis perform europ franchis
durabl import theme eu biosimilar enter octob look
build-out imbruvica label includ interim result mantl cell lymphoma shine
 follicular lymphoma selen follow r/r cll approv next venclexta catalyst
includ phase multipl myeloma mm read-out fda/ema action risankizumab
psoriasi expect plan submit upadacitinib nda ra aim
launch orilissa elagolix treatment endometriosi august see note titl orilissa
elagolix approv clean label endometriosi follow posit result orilissa
second replic trial elari uterin fibroid uf mid-march see note
expect full data two studi upcom medic meet american
societi reproduct medicin asrm oct denver data uf snda
assum
page
page
productsepsconsensusactualno ofdeltadelta chg us statementepsconsensusactualno ofdeltadelta chg incom expens ofdeltadeltamargin diff yoy mnbpsgross actualvari vs strhabbv actualvari vs strhstrh estimatesstrh estimatesvari vs strhabbv actualstrh estim abbvi inc
page
product rang rang rang rang rang midpoint strh estimatesconsensu total growth usnot growth ex-usnot peak sale assum biosimilar entri globalnot usnot viekira mavyret globalnot viekira mavyret us growth growth growth weight base approv r/r clllupron provid flat yoy flat yoy flat provid flat yoy flat yoy flat provid flat yoy flat yoy flat incom totalnot provid approach fx impact fx marginnot sale sale provid marginnot expensenot ratenot rate rise next year rate lowernet incomenot providednot providednot providednot providednot epsnot outstand dilut providednot providednot providednot providednot indic rang updat impli us ex-u rang abbvi inc
valuat risk
price target assum trade ep premium major
biopharmaceut peer group expect abbv trade premium group settl
us patent disput humira pipelin matur multipl data read out immunolog
hematolog oncolog asset play model assum humira total sale account
sale immunolog hematology/oncolog sale new product
label expans exist asset rise sale
risk rate price target includ earlier expect humira biosimilar competit
us market addit assum compani abl gener revenu
pipelin lower humira total revenu clinic regulatori
commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-
elagolix etc could forc look extern acceler diversif sale prior
humira loss exclus us invest risk relat pharmaceut industri gener
includ continu price risk payer especi europ polit risk product develop
risk regulatori risk commerci risk legal risk patent challeng
compani mention note
neurocrin rate
rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
